Samabriva

What Samabriva does

Samabriva is a French biotechnology company founded in 2011 and headquartered in Amiens, France, developing a proprietary plant-based bioproduction platform for manufacturing high-value molecules. The platform is designed to enable sustainable, controlled, and scalable production of complex molecules that may be difficult or costly to manufacture through traditional chemical synthesis, microbial fermentation, or mammalian cell systems, positioning it as a precision biomanufacturing alternative.

The company's commercial focus spans two verticals: pharmaceutical companies seeking novel manufacturing routes for active ingredients, and cosmetics and personal-care players looking for natural-based ingredient production. Its core technology is described as a single unified platform rather than discrete products, and Samabriva's differentiated value proposition rests on process novelty — leveraging plant-based systems rather than microbial or mammalian bioreactors — combined with the regulatory and sustainability benefits that plant-derived manufacturing can offer in regulated end markets.

Samabriva operates a sales-led B2B go-to-market, engaging enterprise customers in pharmaceuticals and cosmetics directly. Pricing is quote-based and negotiated on a per-engagement basis, and the implied revenue model centers on contract manufacturing, platform licensing, or development partnerships. The company is pre-commercial in disclosed terms: it raised a €4 million Series-A in December 2023 co-led by Noshaq and Investsud Tech, with proceeds earmarked for building a production site in Belgium and expanding R&D. Current headcount is in the 11-50 range, no customer logos or revenue figures have been disclosed, the company's website shows a maintenance page, and Marina Guillet is identified as CEO.

Name

Samabriva

Website

https://samabriva.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Samabriva is a French biotech developing a proprietary plant-based bioproduction platform for sustainable, scalable manufacturing of high-value molecules serving pharmaceutical and cosmetics enterprise customers.

Ownership category

akta.pro rank

Product category

Precision Biomanufacturing Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medicinal and Botanical Manufacturing (325411)

SIC

Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)

akta.pro industry

PRIMARYHLAAAJAF

Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling)

Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)

SECONDARYHLAAAIAD

Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

• Plant bioproduction platform
• Precision biomanufacturing services
• Pharmaceutical molecule production
• Cosmetics ingredient manufacturing
• Sustainable biological manufacturing

Headquarters

HQ city

Amiens

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Bioproduction Platform Services: Revenue model not explicitly disclosed. As a precision biomanufacturing company targeting pharmaceuticals and cosmetics, the company likely generates revenue through contract manufacturing services, licensing of production platform, or development partnerships with biotech and cosmetic companies. Currently in Series-A stage with production facility expansion planned in Belgium.

Go-to-market motion1 record

Marketing channels1 record

Core offering

Samabriva develops and operates a plant-based bioproduction platform that manufactures high-value molecules for the pharmaceutical and cosmetics industries. The platform enables sustainable, controlled, and scalable production as an alternative to traditional chemical synthesis or microbial fermentation. The company sells contract bioproduction services, platform licensing, and development partnerships to enterprise customers in pharmaceuticals and cosmetics.

Product overview

Samabriva offers a unified plant-based bioproduction platform focused on precision biomanufacturing for high-value molecules. The platform targets the pharmaceuticals and cosmetics industries, enabling more sustainable, controlled, and scalable manufacturing through innovative plant-based production solutions.

Differentiator

Problem solved

Functional benefit

Products and services

• Plant-based Bioproduction Platform A proprietary plant-based bioproduction platform for developing and manufacturing high-value molecules, enabling sustainable, controlled, and scalable production for pharmaceutical and cosmetics applications. Targeted at enterprise pharmaceutical and cosmetics companies seeking alternative manufacturing methods to traditional chemical synthesis or microbial fermentation.

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Direct peers

• iBio: US-based biotech with a plant-based biomanufacturing platform (FastPharming) using transient expression in Nicotiana benthamiana. Competes in the same plant molecular farming category for therapeutic proteins and vaccines.
• Kentucky BioProcessing: US contract manufacturer specializing in tobacco plant-based expression of recombinant proteins and vaccines for pharma clients. Closely comparable business model as a plant-based CMO for high-value pharmaceutical molecules.
• Protalix Biotherapeutics: Israeli biotech using plant cell-based bioproduction (ProCellEx platform in carrot/rhubarb cells) to manufacture therapeutic proteins for pharma. Directly comparable as a plant-based biomanufacturer targeting regulated pharmaceutical applications, with FDA-approved products (Elelyso).
• Leaf Expression Systems: UK-based plant-based expression company using Nicotiana benthamiana for producing recombinant proteins, vaccines, and complex molecules. Comparable as a European plant-based bioproduction peer with similar target customer base.
• Planet Biotechnology: US biotech producing therapeutic antibodies and other proteins in tobacco plants for pharmaceutical applications. Operates in the same plant-made pharmaceutical category as Samabriva.
• Cape Bio Pharmatechnology: South African biotech using plant-based expression for pharmaceutical and research reagents production. Operates in the same plant molecular farming category targeting therapeutics and high-value molecules.

Regional players

• Moolec Science: Luxembourg/US food-tech using plant molecular farming to produce animal proteins in crops (e.g., pork protein in safflower). Uses similar plant-based expression technology but targets food ingredients rather than pharma/cosmetics, with partial overlap in plant-made molecule production.

Broad incumbents

• Medicago (Mitsubishi Tanabe Pharma): Canadian plant-based vaccine developer (acquired by Mitsubishi) using Nicotiana-based virus-like particle production. Most scaled commercial plant-based biomanufacturer; provides a reference point for the category's commercial viability.

Emerging players

• BioBetter: Israeli food-tech using tobacco plant-based expression to produce growth factors for the cultivated meat industry. Overlaps in plant-based bioproduction platform technology, but targets adjacent food-tech market rather than pharma/cosmetics.
• ORF Genetics: Icelandic biotech using barley-based plant expression to produce growth factors and other proteins for cosmetics and skincare. Directly comparable in the plant-based + cosmetics intersection, but with a different chassis organism.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/samabriva

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Samabriva